MSCV JMJD3 Citations (7)
Originally described in: Control of differentiation in a self-renewing mammalian tissue by the histone demethylase JMJD3.Sen GL, Webster DE, Barragan DI, Chang HY, Khavari PA Genes Dev. 2008 Jul 15. 22(14):1865-70. PubMed Journal
Articles Citing MSCV JMJD3
| Articles |
|---|
| UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia. Benyoucef A, Palii CG, Wang C, Porter CJ, Chu A, Dai F, Tremblay V, Rakopoulos P, Singh K, Huang S, Pflumio F, Hebert J, Couture JF, Perkins TJ, Ge K, Dilworth FJ, Brand M. Genes Dev. 2016 Mar 1;30(5):508-21. doi: 10.1101/gad.276790.115. PubMed |
| Regulation of the JMJD3 (KDM6B) histone demethylase in glioblastoma stem cells by STAT3. Sherry-Lynes MM, Sengupta S, Kulkarni S, Cochran BH. PLoS One. 2017 Apr 6;12(4):e0174775. doi: 10.1371/journal.pone.0174775. eCollection 2017. PubMed |
| Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B. Al Labban D, Jo SH, Ostano P, Saglietti C, Bongiovanni M, Panizzon R, Dotto GP. J Clin Invest. 2018 Jun 1;128(6):2581-2599. doi: 10.1172/JCI96915. Epub 2018 May 14. PubMed |
| Histone demethylase KDM6B has an anti-tumorigenic function in neuroblastoma by promoting differentiation. Yang L, Zha Y, Ding J, Ye B, Liu M, Yan C, Dong Z, Cui H, Ding HF. Oncogenesis. 2019 Jan 4;8(1):3. doi: 10.1038/s41389-018-0112-0. PubMed |
| KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma. D'Oto A, Fang J, Jin H, Xu B, Singh S, Mullasseril A, Jones V, Abu-Zaid A, von Buttlar X, Cooke B, Hu D, Shohet J, Murphy AJ, Davidoff AM, Yang J. Nat Commun. 2021 Dec 10;12(1):7204. doi: 10.1038/s41467-021-27502-2. PubMed |
| KDM6B promotes PARthanatos via suppression of O6-methylguanine DNA methyltransferase repair and sustained checkpoint response. Yang M, Wang C, Zhou M, Bao L, Wang Y, Kumar A, Xing C, Luo W, Wang Y. Nucleic Acids Res. 2022 Jun 24;50(11):6313-6331. doi: 10.1093/nar/gkac471. PubMed |
| Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters. van Gils N, Verhagen HJMP, Broux M, Martianez T, Denkers F, Vermue E, Rutten A, Csikos T, Demeyer S, Cil M, Al M, Cools J, Janssen JJWM, Ossenkoppele GJ, Menezes RX, Smit L. iScience. 2022 Aug 25;25(9):105013. doi: 10.1016/j.isci.2022.105013. eCollection 2022 Sep 16. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.